Publicaciones en colaboración con investigadores/as de University of Texas MD Anderson Cancer Center (20)

2022

  1. Circulating Tumor and Immune Cells for Minimally Invasive Risk Stratification of Smoldering Multiple Myeloma

    Clinical cancer research : an official journal of the American Association for Cancer Research, Vol. 28, Núm. 21, pp. 4771-4781

2020

  1. Elotuzumab, lenalidomide, and dexamethasone in RRMM: final overall survival results from the phase 3 randomized ELOQUENT-2 study

    Blood Cancer Journal, Vol. 10, Núm. 9

2019

  1. Pembrolizumab combined with lenalidomide and low-dose dexamethasone for relapsed or refractory multiple myeloma: phase I KEYNOTE-023 study

    British Journal of Haematology

2017

  1. A retrospective analysis of 3954 patients in phase 2/3 trials of bortezomib for the treatment of multiple myeloma: towards providing a benchmark for the cardiac safety profile of proteasome inhibition in multiple myeloma

    British Journal of Haematology, Vol. 178, Núm. 4, pp. 547-560

2015

  1. American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multiple Myeloma

    Biology of Blood and Marrow Transplantation, Vol. 21, Núm. 12, pp. 2039-2051

  2. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma

    New England Journal of Medicine, Vol. 372, Núm. 2, pp. 142-152

2014

  1. International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation

    Journal of Clinical Oncology, Vol. 32, Núm. 6, pp. 587-600

  2. Phase 2 randomized study of bortezomib-melphalan-prednisone with or without siltuximab (anti-IL-6) in multiple myeloma

    Blood, Vol. 123, Núm. 26, pp. 4136-4142

2013

  1. Plasma cell leukemia: Consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group

    Leukemia, Vol. 27, Núm. 4, pp. 780-791

2012

  1. IMWG consensus on maintenance therapy in multiple myeloma

    Blood, Vol. 119, Núm. 13, pp. 3003-3015

  2. Proteasome inhibitors in multiple myeloma: 10 Years later

    Blood, Vol. 120, Núm. 5, pp. 947-959

2011

  1. Consensus recommendations for standard investigative workup: Report of the International Myeloma Workshop Consensus Panel 3

    Blood

  2. Consensus recommendations for the uniform reporting of clinical trials: Report of the International Myeloma Workshop Consensus Panel 1

    Blood

  3. Effects of lenalidomide and dexamethasone treatment duration on survival in patients with relapsed or refractory multiple myeloma treated with lenalidomide and dexamethasone

    Clinical Lymphoma, Myeloma and Leukemia, Vol. 11, Núm. 1, pp. 38-43

  4. Efficacy and safety of pegylated liposomal doxorubicin in combination with bortezomib for multiple myeloma: Effects of adverse prognostic factors on outcome

    Clinical Lymphoma, Myeloma and Leukemia, Vol. 11, Núm. 1, pp. 44-49

2010

  1. Monoclonal gammopathy of undetermined significance: A consensus statement: Guideline

    British Journal of Haematology, Vol. 150, Núm. 1, pp. 28-38

2009

  1. International myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100)

    Leukemia, Vol. 23, Núm. 10, pp. 1904-1912

  2. Lenalidomide in combination with dexamethasone at first relapse in comparison with its use as later salvage therapy in relapsed or refractory multiple myeloma

    European Journal of Haematology, Vol. 82, Núm. 6, pp. 426-432

2008

  1. Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma

    Leukemia, Vol. 22, Núm. 2, pp. 414-423

2003

  1. Allogeneic hematopoietic stem cell transplantation with reduced-intensity conditioning in acute lymphoblastic leukemia: A feasibility study

    Haematologica, Vol. 88, Núm. 5, pp. 555-560